Results 31 to 40 of about 3,274 (173)
Development of withaferin A analogs as probes of angiogenesis [PDF]
Bioorganic & Medicinal Chemistry Letters, 2006 The natural product withaferin A (WFA) is a potent angiogenesis inhibitor and it targets the ubiquitin-proteasome pathway in vascular endothelial cells. We generated a biotinylated affinity analog WFA-LC(2)B for use as a probe to study angiogenesis.
Yasuno, Yokota +4 more
openaire +2 more sources
Pharmaceuticals, 2023 Cancer represents the second most deadly disease and one of the most important public health concerns worldwide. Surgery, chemotherapy, radiation therapy, and immune therapy are the major types of treatment strategies that have been implemented in cancer
Suneel Kumar +9 more
doaj +1 more source
Scientific Reports, 2021 Poor bioavailability due to the inability to cross the cell membrane is one of the major reasons for the failure of a drug in clinical trials. We have used molecular dynamics simulations to predict the membrane permeability of natural drugs—withanolides (
Renu Wadhwa +8 more
doaj +1 more source
Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
Biomedicines, 2020 Withaferin A (WA), a manifold studied, C28-steroidal lactone withanolide found in Withania somnifera. Given its unique beneficial effects, it has gathered attention in the era of modern science.
Tapan Behl +7 more
doaj +1 more source
Withaferin A: From Ancient Remedy to Potential Drug Candidate [PDF]
Molecules, 2021 Withaferin A (WA) is a pivotal withanolide that has conquered a conspicuous place in research, owning to its multidimensional biological properties. It is an abundant constituent in Withania somnifera Dunal. (Ashwagandha, WS) that is one of the prehistoric pivotal remedies in Ayurveda.
Tahira Sultana +6 more
openaire +4 more sources
Withaferin A Improves Nonalcoholic Steatohepatitis in Mice [PDF]
The Journal of Pharmacology and Experimental Therapeutics, 2019 Nonalcoholic steatohepatitis (NASH) is the progressive stage of nonalcoholic fatty liver disease that highly increases the risk of cirrhosis and liver cancer, and there are few therapeutic options available in the clinic. Withaferin A (WA), extracted from the ayurvedic medicine Withania somnifera, has a wide range of pharmacological activities; however,
Daxesh P, Patel +6 more
openaire +2 more sources
Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line [PDF]
Clinical and Molecular Hepatology, 2020 Background/Aims Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality rate in patients suffering from liver diseases. The drug of choice used in advanced-stage of HCC is sorafenib.
Ankita Makol +5 more
doaj +1 more source
Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling
Journal of Ovarian Research, 2019 Background Ovarian cancer is the fifth leading cause of cancer-related deaths amongst women in the United States. Cachexia is the primary cause of death in approximately 30% of cancer patients, and is often evidenced in ovarian cancer patients. We tested
Alex R. Straughn, Sham S. Kakar
doaj +1 more source
Evaluation of the geroprotective effects of withaferin A in Drosophila melanogaster
Aging, 2021 Withanolides are a class of compounds usually found in plant extracts which are an attractive geroprotective drug design starting point. We evaluated the geroprotective properties of Withaferin A (WA) in vivo using the Drosophila model. Flies were supplemented by nutrient medium with WA (at a concentration of 1, 10, or 100 μM dissolved in ethanol) for ...
Koval, Liubov +4 more
openaire +2 more sources
Withaferin A inhibits osteosarcoma cells through inactivation of Notch-1 signalling
Bangladesh Journal of Pharmacology, 2014 Human osteosarcoma cells were treated with withaferin A and the antiproliferative activity was evaluated by the 3-(4, 5 dimethyl-thiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assays.
Yang Chen +4 more
doaj +1 more source